Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. The company is headquartered in Menlo Park, California and currently employs 28 full-time employees. The company went IPO on 2000-07-21. The firm is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
Follow-Up Questions
Who is the CEO of Oruka Therapeutics Inc?
Dr. Lawrence Klein is the President of Oruka Therapeutics Inc, joining the firm since 2024.
What is the price performance of ORKA stock?
The current price of ORKA is $16.52, it has decreased 0.33% in the last trading day.
What are the primary business themes or industries for Oruka Therapeutics Inc?
Oruka Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Oruka Therapeutics Inc market cap?
Oruka Therapeutics Inc's current market cap is $618.8M
Is Oruka Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Oruka Therapeutics Inc, including 8 strong buy, 6 buy, 1 hold, 0 sell, and 8 strong sell
